Opinion: Calculating Cancer

How a growing partnership between oncologists and mathematicians is moving research forward.

Written byAlexander (Sandy) Anderson and Robert Gatenby
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

SXC.HU, HISKSCancer is a dynamic, adaptive system consisting of billions of normal and tumor cells interacting at multiple spatial and temporal scales. To many cancer biologists and oncologists, the complexity of cancer seems beyond comprehension. So it is not surprising that attempts to develop mathematical models of cancer and therapies have typically been dismissed. Cancer, it would appear to some, is too complicated to model. But this bias ignores an increasingly mundane component of modern life—weather forecasts. By using sophisticated computational models to integrate large, continuously updated datasets organized with the fundamental laws of physics, meteorologists can characterize complex weather systems sufficiently well to accurately predict their behavior.

In 2008, our institution, Moffitt Cancer Center, eschewed the conventional wisdom and formed the department of integrated mathematical oncology (IMO). The applied mathematicians, physicists, and computer scientists who make up the IMO are expected to collaborate with cancer biologists and oncologists to examine cancer as an evolving complex, dynamical system. The goal is not to do new mathematics, but to use mathematics as a tool to do new biology. IMO brings a fresh perspective that focuses on identifying key principles and parameters of a given cancer rather than the more traditional reductionist view of ever more detailed investigation of its component parts. We hold an annual five-day competition in which four teams—each made up of clinical, experimental, and theoretical members—are charged with solving a cancer ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies